BPH Medical & Surgical Management Guideline Panel Meeting (2020)

December 3, 2020

The panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelist will inquire about aspects of the evidence and the methodologist will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods of medical and surgical management of BPH.

Target Audience

Urologists

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for the diagnosis and management of BPH.
  2. Recommend appropriate diagnostic and treatment options for BPH.
  3. Apply improved critical thinking skills to medical literature reviews.
Course summary
Available credit: 
  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Non-Physician Participation
Course opens: 
12/03/2020
Course expires: 
12/03/2023
Event starts: 
12/03/2020 - 9:00am EST
Event ends: 
12/03/2020 - 3:00pm EST
Rating: 
0

Thursday, December 3, 2020

9:00am                 Welcome & Introductions                                                                      Brooke Bixler                                                                                                                                         

9:10am                 Conflict of Interest Disclosures and Panel Responsibilities              Brooke Bixler

9:20am                 Guidelines Stages Overview                                                                   Brooke Bixler

9:30am                 Surgical Management of BPH Evidence Overview                              Dr. Shalini Selvarajah

10:15am              Surgical Management of BPH Discussion and Update                        Panel

                                10:15am- 10:30am           Evaluation and Preop Testing/ Surgical Therapy

                                10:30am- 11:30am           MIST

                                11:30-12:15pm                  New Statements/Formatting Review/Nomenclature

                                                                                  - Check follow-up data for each MIST (i.e. 2 years, 3 years, 5 years…) and make consistent recommendations throughout the document based on follow-up data.

                                                                                  - Discuss adding lower prostate volume limits to Guidelines (i.e. PUL and Rezum) so that they align with the Aquablation statement.

12:15pm              Break/ Lunch (Working Lunch if needed)

12:45pm              Medical BPH Evidence Report Update Overview                                 Dr. Tim Wilt

1:15pm                 Review of Medical BPH Statements                                                       Panel    

                                1:00pm-1:10pm                Follow-up Evaluation

                                1:10pm- 1:30pm               Alpha blockers

                                1:30pm- 1:40pm               ACH

                                1:40pm-2:00pm                5ARI

                                2:00pm- 2:10pm               PDE5i

                                2:10pm- 2:30pm               AUR Outcomes

                                2:30pm- 2:50pm               Combination Therapy

3:00pm                 Recap                                                                                                         Brooke Bixler                                                        

NameCompanyRoleFinancial
J. Kellogg Parsons, MD: Panel ChairMDX HealthConsultant or AdvisorNo
 DendreonLeadership PositionYes

Victor Nitti, MD: Education Council Chair

AstellasHealth PublishingNo
 AllerganHealth PublishingNo
 Serenity PharmaceuticalsInvestment InterestYes
 MedtronicScientific Study or TrialNo
Jodi Antonelli, MD: COI Review Work Group ChairBoston ScientificConsultant or AdvisorYes
 Cook MedicalConsultant or AdvisorYes
Brooke Bixler: AUA StaffNothing to disclose  
Timothy Wilt, PhD: MethodologistNothing to disclose  

 

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

 

Available Credit

  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Non-Physician Participation
Please login or register to take this course.